Kyverna Therapeutics has had the biologics licence application for mivocabtagene autoleucel accepted by US health authorities, the first regulatory submission for an autologous CAR-T therapy in autoimmunity, seeking approval in stiff person syndrome (SPS). Mivocabtagene autoleucel is a fully human, CD28-co-stimulated CD19 CAR-T designed to deeply deplete B-cells and reset the immune system, with more than 100 patients treated to date and a stable, well-tolerated safety profile supporting the filing.
The clinical signal is meaningful. In the Phase II KYSA-8 study, timed 25-foot walk improved by 46% at week 16 and 49% at month 12, with over a third of patients completing the test within five seconds, while myasthenia gravis patients showed rapid, deep responses on MG-ADL and QMG scores within two weeks.
Kyverna plans a registrational Phase III in myasthenia gravis in 2027, positioning mivocabtagene autoleucel as a potential one-time treatment that could replace chronic immunosuppression.

Email us at pmc@pharmcube.com for a free database trial, exclusive reports, or a 1-on-1 consultation